Back to Markets
LELENZ Therapeutics Inc

LENZ Therapeutics Inc

LENZ
Health CareBiotechnology: Biological Products (No Diagnostic Substances)

$7.78

-0.210000 (-2.63%)

As of 05/29/26 EDT · USD

Compare
Low: $6.61Current: $7.78High: $50.40

Key Statistics

Open

$8.21

Day High

$8.49

Day Low

$7.75

Prev. Close

$7.99

VolumeShares traded today.

765.41K

Avg. VolumeAverage daily volume.

Market CapTotal value of all shares = price × shares outstanding.

$243.94M

P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.

-2.16

Forward P/EP/E based on forecast next-year earnings.

P/B RatioPrice-to-Book: share price ÷ book value per share.

52W HighHighest price over the past 52 weeks.

$50.40

52W LowLowest price over the past 52 weeks.

$6.61

50D MAAverage closing price over the last 50 trading days.

$9.02

200D MAAverage closing price over the last 200 trading days.

$22.30

Dividend YieldAnnual dividend ÷ share price, as a %.

BetaVolatility vs the market. >1 = more volatile than the S&P 500.

Performance

1W

+3.5%

1M

-14.0%

6M

-74.0%

YTD

-51.4%

1Y

-73.3%

About

Aceclidine is a parasympathomimetic cholinergic drug that functions as a muscarinic acetylcholine receptor agonist. It is used in ophthalmology as a miotic agent to constrict the pupil. Historically used in Europe for the treatment of glaucoma, aceclidine received its first U.S. approval in 2025 under the brand name Vizz as a topical eye drop for the correction of presbyopia. Its mechanism of action produces pupil contraction with a relatively minimal effect on the ciliary muscle, which improves near visual acuity through a "pinhole" depth-of-field effect without inducing significant accommodative spasm.

Company Facts

SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CurrencyUSD

Sentiment

Latest News

Social Noise

Price Alerts

Loading…

Trade LENZ

Brokers available in your region (US)

Affiliate links — we may earn a commission. CFDs are risky.